Serum homocysteine levels in renal transplant recipients with and without hypercholesterolemia;Avaliação dos níveis séricos de homocisteína em transplantados renais com e sem hipercolesterolemia

Arquivos Brasileiros de Cardiologia

Volumn 89, Issue 3, 2007, Pages 170-175

  Piovesan, Fabiana ^a   Veronese, Francisco José Veríssimo ^a   Santos, Auri Ferreira ^a   Pozza, Roberta ^a   Sarturi, Péricles Serafim ^a   Tognon, Alexandre ^a   Garcia, Valter Duro ^a   Keitel, Elizete ^a   Saitovitch, David ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Dyslipidemia; Hyperhomocysteinemia; Renal transplantation

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CYCLOSPORIN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; BIOLOGICAL MARKER; CREATININE; IMMUNOSUPPRESSIVE AGENT; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AMINO ACID BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE CLEARANCE; DYSLIPIDEMIA; FEMALE; GRAFT RECIPIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; POSTOPERATIVE PERIOD; PREVALENCE; PROTEINURIA; STATISTICAL SIGNIFICANCE; AGE; BLOOD; BRAZIL; DRUG EFFECT; EPIDEMIOLOGY; MIDDLE AGED; REFERENCE VALUE; TIME;

ADULT; AGE FACTORS; BIOLOGICAL MARKERS; BRAZIL; CHOLESTEROL; CREATININE; CYCLOSPORINE; DYSLIPIDEMIAS; EPIDEMIOLOGIC METHODS; FEMALE; HOMOCYSTEINE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTEINURIA; REFERENCE VALUES; TIME FACTORS; TRIGLYCERIDES;

EID: 37449000091     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Bostom AG, Shemin D, Gohh RY, Beaulieu AJ, Bagley P, Massy ZA, et al. Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. Kidney Int Suppl. 2001;78: S246-52.
2. Massy ZA, Chadefaux-Vekemans B, Chevalier A, Bader CA, Drueke TB, Legendre C, et al. Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant. 1994;9 (8): 1103-8.
3. Ducloux D, Ruedin C, Gibey R, Vautrin P, Bresson-Vautrin C, Rebibou JM, et al. Prevalence, determinants, and clinical significance of hyperhomocyst(e)inaemia in renal-transplant recipients. Nephrol Dial Transplant. 1998; 13 (11): 2890-3.
4. Santos AF, Keitel E, Bittar AE, Neumann J, Fuchs FD, Goldani JC, et al. Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study. Transplant Proc. 2001;33(1-2): 194-5.
5. Roodnat JI, Mulder PG, Zietse R, Rischen-Vos J, Van Riemsdijk IC, Ijzermans JN, et al. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation. 2000;69(8): 1704-10.
6. Perna AF, Ingrosso D, Castaldo P, Galletti P, De Santo NG. Homocysteine and transmethylation in uremia. Kidney Int Suppl. 2001;78: S230-3.
7. Fonseca I, Queiros J, Santos MJ, Mendonça D, Henriques AC, Sarmento AM, et al. Hyperhomocysteinemia in renal transplantation: preliminary results. Tansplant Proc. 2000; 32(8): 2602-4.
8. Beaulieu AJ, Lapane KL, Gohh RY, Selhub J, Monaco AP, Dworkin L, et al. Short-term reproducibility of total homocysteine determinations in stable renal transplant recipients. Tansplant Proc. 1999; 31 (5): 2121-3.
9. Sunder-Plassmann G, Floth A, Fodinger M. Hyperhomocysteinemia in organ transplantation. Curr Opin Urol. 2000; 10 (2): 87-94.
10. Ducloux D, Motte G, Nguyen NU, Abdelfath A, Gibey R, Chalopin JM. Homocysteine, nutritional status and insulin in renal transplant recipients. Nephrol Dial Transplant. 2002; 17 (9): 1674-7.
11. Winkelmayer WC, Kramar R, Curhan GC, Chandraker A, Endler G, Fodinger M, et al. Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study. J Am Soc Nephrol. 2005;16 (1): 255-60.
12. Kes P. Hyperhomocysteinemia in end-stage renal failure. Acta Med Croatica. 2000; 54 (4-5): 175-81.
13. Mangoni AA, Jackson SH. Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med. 2002; 112 (7): 556-65.
14. Locsey L, Asztalos L, Dan A, Kinces Z, Berczi C, Sziki G. Changes in cardiovascular risk factors after renal transplantation. Magy Seb. 2001; 54 (2): 101-4.
15. Ducloux D, Fournier V, Rebibou JM, Bresson-Vautrin C, Gibey R, Chalopin JM. Hyperhomocyst(e)inemia in renal transplant recipients with and without cyclosporine. Clin Nephrol. 1998; 49 (4): 232-5.
16. Van Guldener C, Stam F, Stehouwer CD. Homocysteine metabolism in renal failure. Kidney Int Suppl. 2001; 78: S234-7.
17. Arnadottir M, Hultberg B, Wahlberg J, Fellstrom B, Dimeny E. Serum totalhomocysteine concentration before and after renal transplantation. Kidney Int. 1998; 54 (4): 1380-4.
18. Bostom AG, Gohh RY, Beaulieu AJ, Han H, Jacques PF, Selhub J, et al. Determinants of fasting plasma total homocysteine levels among chronic stable renal transplant recipients. Transplantation. 1999; 68 (2): 257-61.
19. Fonseca V, Guba SC, Fink LM. Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis. Endocr Rev. 1999; 20 (5): 738-59.
20. Kim SI, Yoo TH, Song HY, Hwang JH, Lee Hy, Han DS, et al. Hyperhomocysteinemia in renal transplant recipients with cyclosporine. Tansplant Proc. 2000; 32 (7): 1878-9.
21. Drüeke TB, Abdulmassih Z, Lacour B, Bader C, Chevalier A, Kreis H. Atherosclerosis and lipid disorders after renal transplantation. Kidney Int Suppl. 1991; 31: S24-8.
22. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997; 337 (4): 230-6.
23. Stoves J, Lindley EJ, Barnfield MC, Burniston MT, Newstead CG. MDRD equation estimates of glomerular filtration rate in potential living kidney donors and renal transplant recipients with impaired graft function. Nephrol Dial Transplant. 2002; 17 (11): 2036-7.
24. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol. 2000; 11 (1): 134-7.
25. Laures AS, Gomez E, Alvarez V, Coto E, Baltar J, Alvarez-Grande J. Influence of anticalcineurinic therapy in plasma homocysteine levels of renal transplant recipients: a prospective study. Transplant Proc. 2003; 35 (5): 1739-41.
26. Quiroga I, Morris-Stiff G, Baboo R, Darby CR, Lord RH, Jurewicz WA. Differential homocysteine levels in renal transplant patients receiving neoral versus tacrolimus. Transplant Proc. 2001; 33 (1-2): 1209-10.
27. Akbas SH, Tuncer M, Gurkan A, Yucetin L, Yavuz A, Demirbas A, et al. Plasma homocysteine levels in renal transplant patients on tacrolimus therapy. Transplant Proc. 2004; 36 (1): 159-60.
28. Maes BD, Vanrenterghem YF. Cyclosporine: advantages versus disadvantages vis-à-vis tacrolimus. Transplant Proc. 2004; 36 (2 Suppl): 40S-9S.